A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)-Reference-Cited by-同舟云学术

A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)

Published:2024-01-13 Issue:2 Volume:15 Page:533-545
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Hirota Yushi,Kakei Yasumasa,Imai Junta,Katagiri Hideki,Ebihara Ken,Wada Jun,Suzuki Junichi,Urakami Tatsuhiko,Omori Takashi,Ogawa Wataru

Funder

Boehringer Ingelheim Japan

Eli Lilly Japan

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13300-023-01526-x.pdf

Reference34 articles.

1. Semple RK, Savage DB, Cochran EK, Gorden P, O’Rahilly S. Genetic syndromes of severe insulin resistance. Endocr Rev. 2011;32:498–514.

2. Ogawa W, Araki E, Ishigaki Y, et al. New classification and diagnostic criteria for insulin resistance syndrome. Diabetol Int. 2022;13:337–43.

3. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976;294:739–45.

4. Musso C, Cochran E, Moran SA, et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004;83:209–22.

5. Takeuchi T, Ishigaki Y, Hirota Y, et al. Clinical characteristics of insulin resistance syndromes: a nationwide survey in Japan. J Diabetes Investig. 2020;11:603–16.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter, open‐label, single‐arm trial of the long‐term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE‐02);Journal of Diabetes Investigation;2024-05-04